Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EBITDA (2020 - 2025)

Vivos Therapeutics' EBITDA history spans 6 years, with the latest figure at -$6.6 million for Q4 2025.

  • Quarterly results put EBITDA at -$6.6 million for Q4 2025, down 143.24% from a year ago — trailing twelve months through Dec 2025 was -$19.2 million (down 78.23% YoY), and the annual figure for FY2025 was -$19.2 million, down 79.87%.
  • EBITDA for Q4 2025 was -$6.6 million at Vivos Therapeutics, down from -$4.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $8.8 million in Q4 2021 to a low of -$6.8 million in Q2 2022.
  • The 5-year median for EBITDA is -$4.2 million (2021), against an average of -$3.7 million.
  • Peak annual rise in EBITDA hit 240.69% in 2021, while the deepest fall reached 226.46% in 2021.
  • Year by year, EBITDA stood at $8.8 million in 2021, then crashed by 165.41% to -$5.8 million in 2022, then soared by 31.75% to -$3.9 million in 2023, then surged by 31.2% to -$2.7 million in 2024, then tumbled by 143.24% to -$6.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$6.6 million, -$4.3 million, and -$4.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.